Charlotte Benson,Christina Messiou,Heather McCarty,Ian Judson,Juan Martin-Liberal,Khin Thway
The Royal Marsden Hospital, Sarcoma Unit, Fulham Road, SW3 6JJ London, UK.email@example.com.
We report the outcome of two patients affected by progressive DT/AF treated with the angiogenesis inhibitor pazopanib in two different institutions. Both patients achieved dramatic improvement in their symptoms and radiological signs of response. The clinical benefit lasted for more than 1 year and it is still ongoing.